Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Biomarker/Laboratory analysis, Treatment	Active	Any age	NCI	CINJ-3330 NCT00161187

Trial Description

Purpose:

When irradiated lymphocytes from a donor are infused into the patient they may help the patient’s immune system kill cancer cells.

This phase II trial is studying the side effects and how well irradiated donor lymphocyte infusion works in treating patients with relapsed or refractory hematologic cancer or solid tumor.

Eligibility:

Eligibility criteria include the following:

• Any age
• Measurable disease
• Received previous standard therapy or not able to undergo standard therapy
• No CNS cancer
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive a 1-hour infusion of irradiated donor lymphocytes on day 1. Treatment may repeat every 2-4 months for up to six courses.

Patients will undergo blood sample collection periodically for laboratory studies.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Roger Strair, MD, PhD, Principal investigator		Ph: 732-235-6044 Email: strairrk@umdnj.edu

U.S.A.
New Jersey
	New Brunswick
	Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
		Clinical Trials Office - Cancer Institute of New Jersey	Ph:  732-235-8675

Registry Information
Official Title		A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes for Patients With Selected Malignancies
Trial Start Date		2000-12-01
Registered in ClinicalTrials.gov		NCT00161187
Date Submitted to PDQ		2007-04-25
Information Last Verified		2008-04-21
NCI Grant/Contract Number		CA72720